文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

CD40配体抑制剂dapirolizumab pegol治疗系统性红斑狼疮的3期试验

Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial.
PubMed 文献 · Lancet · 2026-05-29

PHOENYCS GO是一项48周、随机、双盲、安慰剂对照的3期试验,纳入321例中重度活动性SLE患者,比较dapirolizumab pegol 24 mg/kg与安慰剂每4周静脉给药联合标准治疗。

要点

  • dapirolizumab pegol组第48周BICLA缓解率50%,安慰剂组35%,差异有统计学意义。
  • 治疗中出现的不良事件发生率两组分别为83%与75%,严重不良事件分别为10%与15%。
  • 输注相关超敏反应发生率3%,严重感染发生率两组分别为4%与6%。

核心结论

  • dapirolizumab pegol可显著改善系统性红斑狼疮患者的疾病活动度,支持其作为SLE治疗选择的进一步研究。

研究设计与样本

  • PHOENYCS GO为48周、随机、双盲、安慰剂对照的3期试验,在25个国家177个中心开展。
  • 321例16岁及以上中重度活动性SLE患者按2:1随机接受dapirolizumab pegol 24 mg/kg或安慰剂每4周静脉给药,联合标准治疗。
  • 主要终点为第48周BICLA缓解率,疗效分析基于改良意向治疗人群,安全性分析纳入所有至少接受一次给药的患者。

主要发现

  • 治疗中出现的不良事件发生率dapirolizumab pegol组为83%(176/213),安慰剂组为75%(81/108)。
  • 严重治疗中出现的不良事件发生率dapirolizumab pegol组为10%(21/213),安慰剂组为15%(16/108)。
  • 输注相关超敏反应发生率为3%(6/213),严重感染发生率dapirolizumab pegol组为4%(8/213),安慰剂组为6%(6/108)。
  • dapirolizumab pegol组发生1例血栓栓塞事件(心肌梗死)和1例死亡(坏疽相关脓毒症)。

关键数值与推荐

  • dapirolizumab pegol给药方案为24 mg/kg静脉输注每4周一次,联合标准治疗。

临床怎么用

  • 对于中重度活动性SLE且标准治疗下仍有疾病活动的患者,dapirolizumab pegol联合标准治疗可提高第48周BICLA缓解率。
  • 用药期间需监测输注相关超敏反应及感染等不良事件。

局限性

  • 6例患者因一家中心不符合GCP而被排除,全分析集为315例。
  • 原文未报告长期安全性数据及亚组分析结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dapirolizumab pegol is a novel CD40 ligand inhibitor. In this phase 3 trial, we aimed to evaluate the efficacy and safety of dapirolizumab pegol in patients with systemic lupus erythematosus (SLE). METHODS: PHOENYCS GO was a 48-week, randomised, double-blind, placebo-controlled, phase 3 trial conducted in 177 centres (hospitals, private practices, and trial centres) in 25 countries. Patients aged 16 years or older with moderate-to-severe, active SLE despite standard-of-care medication were randomly assigned (2:1), via an interactive web response system, to intravenous dapirolizumab pegol 24 mg/kg or placebo every 4 weeks in addition to standard of care. Patients, investigators, and funders were blinded to treatment assignments. The primary outcome was British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response at week 48. Efficacy analyses were conducted on a modified intention-to-treat population. Safety analyses included all randomly assigned patients who received at least one study medication dose. This trial is registered with ClinicalTrials.gov (NCT04294667) and is completed. FINDINGS: Between Aug 12, 2020, and June 8, 2023, 643 patients were screened and 321 patients were randomly assigned to dapirolizumab pegol (n=213) or placebo (n=108) plus standard of care. All randomly assigned patients received at least one dose of study medication. Six patients were excluded due to non-compliance of one site with Good Clinical Practice guidelines; therefore, the full-analysis set included 315 patients (293 female, 22 male). A significantly greater proportion of patients receiving dapirolizumab pegol (50% [103/208]) versus placebo (35% [37/107]) had BICLA response at week 48 (p=0·011; difference 14·6; 95% CI 3·3-25·8). Treatment-emergent adverse events occurred in 83% (176/213) of patients receiving dapirolizumab pegol versus 75% (81/108) receiving placebo. Serious treatment-emergent adverse events occurred in 10% (21/213) of patients receiving dapirolizumab pegol versus 15% (16/108) receiving placebo. Hypersensitivity reactions during infusion occurred in 3% (6/213) of patients receiving dapirolizumab pegol. Serious infections occurred in 4% (8/213) and 6% (6/108) of patients receiving dapirolizumab pegol and placebo, respectively. One thromboembolic event (myocardial infarction) occurred in one patient in the dapirolizumab pegol group and one death (gangrene-related sepsis) occurred in another patient in the dapirolizumab pegol group. INTERPRETATION: Dapirolizumab pegol was associated with significant improvement in disease activity in patients with SLE. These findings support the further investigation of dapirolizumab pegol as a treatment option for SLE. FUNDING: UCB and Biogen.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Clowse MEB, Isenberg DA, Merrill JT, et al. Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2026. PMID: 42214397. doi:10.1016/S0140-6736(26)00691-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。